Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2403-2409

  Shitara, K ^a   Matsuo, K ^a   Takahari, D ^a   Yokota, T ^a   Shibata, T ^a   Ura, T ^a   Ito, S ^a   Sawaki, A ^a   Tajika, M ^a   Kawai, H ^a   Muro, K ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Neutropenia; Paclitaxel; Prognostic factor

Indexed keywords

ANTIBIOTIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78649465796     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq248     Document Type: Article

References (14)

1. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297-1302.
2. Poikonen P, Saarto T, Lundin J et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80: 1763-1766.
3. Samson MK, Rivkin SE, Jones SE et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 1984; 53: 1029-1035.
4. Rankin EM, Mill L, Kaye SB et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992; 65: 275-281.
5. Hovgaard D, Nissen NI. A phase I/II study of dose and administration of nonglycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leuk Lymphoma 1992; 7: 217-224.
6. Di Maio M, Gridelli C, Gallo C et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6: 669-677.
7. Kishida Y, Kawahara M, Teramukai S et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 2009; 101(9): 1537-1542.
8. Yamanaka T, Matsumoto S, Teramukai S et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007; 97: 37-42.
9. Shitara K, Matsuo K, Takahari D et al. Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 2009; 45: 1757-1763.
10. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
11. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
12. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374(9698): 1331-1338.
13. Hironaka S, Zenda S, Boku N et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9(1): 14-18.
14. Kodera Y, Ito S, Mochizuki Y et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007; 27(4C): 2667-2671.